<DOC>
	<DOCNO>NCT00227032</DOCNO>
	<brief_summary>RATIONALE : Erlotinib may stop growth tumor cell block enzymes need cell growth . PURPOSE : This phase I trial study side effect best dose erlotinib treat patient progressive glioblastoma multiforme .</brief_summary>
	<brief_title>Erlotinib Treating Patients With Progressive Glioblastoma Multiforme</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine maximum tolerate dose erlotinib hydrochloride administer escalating dos every 72 hour patient progressive glioblastoma multiforme . Secondary - Determine relationship plasma cerebrospinal fluid ( CSF ) concentration erlotinib hydrochloride patient . - Determine relationship plasma CSF concentration erlotinib hydrochloride patient receive concurrent enzyme-inducing antiepileptic drug ( EIAEDs ) v receive concurrent EIAEDs . - Correlate CYP3A4 activity , measure midazolam hydrochloride clearance , plasma clearance erlotinib hydrochloride patient . - Correlate CYP1A2 activity , measure 4-hour paraxanthine ( 17X ) /caffeine ( 137X ) plasma ratio , plasma clearance erlotinib hydrochloride patient . - Determine , preliminarily , objective response disease progression patient treat erlotinib hydrochloride . - Correlate presence EGFRvIII mutation objective response disease progression patient treat erlotinib hydrochloride . OUTLINE : This open-label , dose-escalation study . Patients stratify accord use concurrent enzyme-inducing antiepileptic drug ( EIAEDs ) ( yes v ) . Patients receive oral erlotinib hydrochloride every 72 hour 28 day . Courses repeat every 28 day absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate doses* erlotinib hydrochloride maximum tolerate dose ( MTD ) determine preliminary result show direct relationship plasma cerebrospinal fluid concentration . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . NOTE : *Interim enrollment patient allow ; patient receive current approve dose erlotinib hydrochloride . Patients undergo blood sample collection periodically day 13 pharmacokinetic study . The pharmacokinetic study comprises midazolam hydrochloride caffeine clearance assessment correlation assessment CYP3A4 activity CYP1A2 activity . Paraffin-embedded frozen tumor tissue obtain patient underwent prior surgical resection analysis wild-type EGFR EGFRvIII mutation immunohistochemistry . Quality life assess baseline 1 month 6 month . After completion study therapy , patient follow periodically .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm glioblastoma multiforme ( highgrade glioma behave clinically and/or radiographically like glioblastoma multiforme ) Progressed firstline therapy ( e.g. , surgery , chemotherapy , radiotherapy ) PATIENT CHARACTERISTICS : Karnofsky performance status 60100 % ANC &gt; 1,500/mm³ Platelet count &gt; 100,000/mm³ Hemoglobin &gt; 8.5 g/dL ALT AST &lt; 2 time upper limit normal ( ULN ) Alkaline phosphatase &lt; 2 time ULN Bilirubin &lt; 1.5 mg/dL Creatinine &lt; 1.5 mg/dL OR creatinine clearance &gt; 50 mL/min Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No diagnosis history significant renal hepatic disease No contraindication ( e.g. , mass effect , brain shift ) lumbar puncture procedure No active infection No diagnosis history corneal abnormalities No diagnosis history malabsorptive syndrome disorder affect gastrointestinal absorption No history hypersensitivity reaction midazolam hydrochloride ( CYP3A4 biomarker ) PRIOR CONCURRENT THERAPY : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>adult giant cell glioblastoma</keyword>
	<keyword>adult gliosarcoma</keyword>
	<keyword>adult glioblastoma</keyword>
	<keyword>recurrent adult brain tumor</keyword>
</DOC>